San Francisco Sentry Investment Group’s Teva Pharmaceuticals TEVA Stock Holding History

San Francisco Sentry Investment Group’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-1,200	Closed	-$21K	–	950
2017 Q3	$21K	Sell	1,200 -2,000	-63%	-$45K	0.01%	546
2017 Q2	$106K	Buy	+3,200	New	+$99K	0.04%	288
2017 Q1	–	Sell	-6,200	Closed	-$225K	–	203
2016 Q4	$225K	Sell	6,200 -500	-7%	-$20K	0.13%	160
2016 Q3	$308K	Hold	6,700	–	–	0.18%	127
2016 Q2	$337K	Hold	6,700	–	–	0.21%	114
2016 Q1	$358K	Hold	6,700	–	–	0.21%	115
2015 Q4	$440K	Hold	6,700	–	–	0.28%	99
2015 Q3	$378K	Sell	6,700 -300	-4%	-$19.5K	0.27%	102
2015 Q2	$414K	Hold	7,000	–	–	0.25%	105
2015 Q1	$436K	Hold	7,000	–	–	0.26%	100
2014 Q4	$403K	Hold	7,000	–	–	0.23%	106
2014 Q3	$376K	Hold	7,000	–	–	0.19%	112
2014 Q2	$367K	Hold	7,000	–	–	0.18%	115
2014 Q1	$370K	Sell	7,000 -300	-4%	-$13.9K	0.12%	150
2013 Q4	$293K	Sell	7,300 -9,825	-57%	-$387K	0.1%	159
2013 Q3	$647K	Sell	17,125 -250	-1%	-$9.75K	0.24%	99
2013 Q2	$681K	Buy	+17,375	New	+$677K	0.25%	87

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

San Francisco Sentry Investment Group's TEVA Position: Q4 2017 in Review

San Francisco Sentry Investment Group sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 1,200 shares — an estimated $21K sold.

San Francisco Sentry Investment Group first reported a position in TEVA in Q2 2013 and held it in 17 quarters. The position peaked at $681K in Q2 2013. 508 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

San Francisco Sentry Investment Group reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
San Francisco Sentry Investment Group sold 1,200 Teva Pharmaceuticals shares in Q4 2017, an estimated $21K.
San Francisco Sentry Investment Group first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 17 quarters.
San Francisco Sentry Investment Group's Teva Pharmaceuticals position peaked at $681K in Q2 2013.
508 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on San Francisco Sentry Investment Group's 13F filing for Q4 2017, filed 7 Feb 2018.